JEONJU-CITY
15.10.2021 09:26:04 CEST | Business Wire | Press release
Jeonju , a UNESCO Creative City of Gastronomy, announced that the 2021 Jeonju Bibimbap Festival, the typical gourmet festival of the city, is to be held on every weekend during October 9 - 31, 2021 in the vicinity of Jeonju Hyanggyo in Jeonju Hanok Village and online.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211015005015/en/
Under the title of the World Bibim Week , the bibimbap festival is designed and supervised by Ryu Jae-hyeon, Executive Director, focusing on a food festival to deliver the best taste while promoting sociability that is represented by ‘mixture’. The event is to take place on a small groups reservation basis.
The four week-festival features ‘day’ programs on each weekend under different themes including Bibim Week (Day for Couples), Vitamin Week (Day for Wives), Protein Week (Day for Husbands) and World Week (Day for Families). And other special and standing programs and special exhibitions are also held.
On the first weekend of the Bibim Week (Day for Couples), the event delivers the life-changing meal program ‘Insaeng Matchan', where selected couples are invited to the best restaurants with splendid views to enjoy the full course meals of experienced chefs.
On the second weekend of Vitamin Week (Day for Wives), healthy foods are served that can relieve stress and be beneficial for diets. The healthy and delicious food program 'Geongang Matchan' offers vegetarian meals, poke made of local food ingredients, and a variety of salads for those who want to experience a vegetarian diet or healthy foods. In addition, ‘Buddhist Monk Daean’, an artisan of temple cuisines, introduces gastronomy art, gastronomy & beautiful story meditation and gastronomic vegetarian foods.
The third weekend of the Protein Week (Day for Husbands) prepares a delicious meat foods program ‘Gogi Matchan' to allow husbands to choose gravy-rich meats depending on their own taste.
The fourth weekend of the festival will feature World Week when family members can experience Oriental and Western tastes and culture. The World Week offers a ‘Gastronomy Halloween’ program and campaigns such as ‘Dining with Parents’.
Standing programs this year include taste concert and experiences joined by artisans of Jeonju traditional foods; ‘tastes and concert’ that allows participants to taste foods and enjoy performances; a ‘gastronomy theater’, a wireless theater showing silent films featuring unusual foods; ‘traditional Korean-style house picnic’ that allows visitors to enjoy foods at quiet and still space of Korean-style houses; and special exhibitions using unoccupied stores along the Jeonju Hyanggyo, a Confucian School.
“A pitiful situation is that the limited number of citizens and tourists can enjoy the festival as only those people who are fully vaccinated against COVID-19 are allowed to participate based on advance reservations in small groups,” said an official at tourism industry division, Jeonju City government. “We look forward to seeing citizens and small business runners feel pleasure and comfort with traditional foods and elegant scenes of Hanok Village of Jeonju, the UNESCO Creative City of Gastronomy”.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211015005015/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio29.4.2026 13:42:00 CEST | Press release
Highlights: Chiesi agreed to acquire KalVista Pharmaceuticals for $27.00 per share in cash, representing an equity consideration of approximately $1.9bnAcquisition adds to Chiesi’s rare immunology portfolio the first oral, on-demand therapy for hereditary angioedema, strengthening Chiesi’s long-term commitment to people living with rare conditionsTransaction expected to close in Q3 2026 Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical group and certified B Corp, and KalVista Pharmaceuticals, Inc.(“KalVista”) (Nasdaq: KALV), today announced that the companies have entered into a definitive agreement under which Chiesi will acquire KalVista (the “Transaction”). The Transaction was unanimously approved by both Chiesi’s and KalVista’s Boards of Directors and is expected to close in Q3 2026, subject to the satisfaction of customary closing conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202604
Pacific Defense Awarded U.S. Marine Corps Contract for Next Generation Electronic Warfare Prototype29.4.2026 13:00:00 CEST | Press release
Award advances SOSA/CMOSS mission system ecosystem and informs future EW fielding decisions Pacific Defense has been awarded a 12-month rapid prototyping contract by the U.S. Marine Corps Systems Command (MARCORSYSCOM), Program Manager for Tactical Communications and Electronic Warfare (PM TCE) to support next-generation electronic warfare (EW) capability evaluation. The effort will assess Modular Open Systems Approach (MOSA) Electronic Warfare (EW) mission systems and their potential in modernizing USMC capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429918712/en/ Pacific Defense's Next Generation Electronic Warfare System enables rapid integration of new hardware and software into a common chassis, accelerating capability insertion while reducing vendor lock and lifecycle costs. Under the contract, Pacific Defense will deliver SOSA/CMOSS-aligned mission systems to enable vehicle-based experimentation by U.S
Visa Accelerates Stablecoin Momentum: Adding Five Blockchains for Settlement29.4.2026 13:00:00 CEST | Press release
Stablecoin settlement pilot sees record growth 50% quarter over quarter, reaching $7B run rate. Today, Visa (NYSE: V) announced that it is adding five blockchains to its global stablecoin settlement pilot, expanding how issuers and acquirers can settle with the network. As stablecoins move into mainstream payment flows, Visa’s stablecoin settlement pilot now supports nine blockchains and has reached a $7 billion annualized stablecoin settlement run rate, up 50% since last quarter. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429143049/en/ Visa is adding support for five additional blockchains, further expanding its multi-chain settlement capabilities. “Our partners are building in a multi-chain world, and they expect their options to reflect that reality,” said Rubail Birwadker, Global Head of Growth Products and Strategic Partnerships, Visa. “Expanding our stablecoin settlement pilot program to more blockchains means o
U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 12:00:00 CEST | Press release
TEVIMBRA plus ZIIHERA and chemotherapy regimen delivered statistically significant median OS of 26.4 months, an unprecedented result in this challenging diseaseResults from the global Phase 3 HERIZON-GEA-01 study demonstrate potential to change clinical practice in advanced HER2+ gastroesophageal adenocarcinoma BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indica
European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 11:30:00 CEST | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom